{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:16Z","timestamp":1790409256101,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Early intervention in smoldering multiple myeloma (SMM) may delay progression to MM. Here, we present the final analysis of the phase 2 CENTAURUS study. In total, 123 patients with intermediate\/high-risk SMM were randomized to IV daratumumab 16 mg\/kg after a long-intense (n\u00a0=\u00a041), intermediate (n\u00a0=\u00a041), or short-intense (n\u00a0=\u00a041) dosing schedule. At a combined median follow-up of 85.2 months, in the long-intense, intermediate, and short-intense arms complete response or better rates were 4.9%, 9.8%, and 0%; overall response rates were 58.5%, 53.7%, and 37.5%; progressive disease\/death rates were 0.096, 0.102, and 0.109 (P\u00a0&amp;lt; .0001 for all arms); and median progression-free survival was not reached, 84.4, and 74.1 months, respectively. Median overall survival was not reached in any arm. Thirty-six patients in the long-intense or intermediate arms continued daratumumab in an optional extension phase after completing 20 cycles of per-protocol treatment. The median duration of study treatment was 44.0 (range, 1.0-91.6), 35.2 (range, 1.9-90.6), and 1.6 (range, 0.1-1.9) months in the long-intense, intermediate, and short-intense arms, respectively. No new safety signals were observed. With extended follow-up (median, \u223c7 years), these data highlight the tolerability of daratumumab and support ongoing trials investigating daratumumab as an early intervention for SMM. This trial was registered at www.ClinicalTrials.gov as #NCT02316106.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025897","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:17:08Z","timestamp":1733761028000},"page":"1658-1669","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"first","affiliation":[{"name":"1Division of Myeloma, Department of Medicine, Sylvester Comprehensive Cancer Center at University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"2Center of Excellence for Multiple Myeloma, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"4Department of Clinical Haematology, Malignant Haematology, and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-6265","authenticated-orcid":false,"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-7464","authenticated-orcid":false,"given":"Matthew W.","family":"Jenner","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University Hospital Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3786-8400","authenticated-orcid":false,"given":"Dean","family":"Smith","sequence":"additional","affiliation":[{"name":"8Department of Haematology, Translational Medical Sciences, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"9Department of Specialized, Diagnostic, and Experimental Medicine, Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"12Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"13German-speaking Myeloma Multicenter Group and Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Vieyra","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Sha","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, LLC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, LLC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Rousseau","sequence":"additional","affiliation":[{"name":"16Janssen Research & Development, LLC, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Dennis","sequence":"additional","affiliation":[{"name":"17Janssen Research & Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"18Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2025041015222431000_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025041015222431000_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsdottir","year":"2023","journal-title":"Nat Med"},{"key":"2025041015222431000_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/BLCTT.S136447","article-title":"Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions","volume":"8","author":"Blum","year":"2018","journal-title":"Blood Lymphat Cancer"},{"issue":"10","key":"2025041015222431000_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"19","key":"2025041015222431000_bib5","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-24-0210","article-title":"Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma","volume":"30","author":"Kazandjian","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025041015222431000_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025041015222431000_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025041015222431000_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/hematology.2021000304","article-title":"Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies","volume":"2021","author":"Visram","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2025041015222431000_bib9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"21","key":"2025041015222431000_bib10","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2025041015222431000_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"issue":"3","key":"2025041015222431000_bib12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2025041015222431000_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2025041015222431000_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry A"},{"issue":"2","key":"2025041015222431000_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025041015222431000_bib16","first-page":"3107","article-title":"Safety and efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed and refractory multiple myeloma: final results from GEN501 and SIRIUS","volume":"130","author":"Usmani","year":"2017","journal-title":"Blood"},{"issue":"10027","key":"2025041015222431000_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"2025041015222431000_bib18","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2025041015222431000_bib19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2025041015222431000_bib20","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025041015222431000_bib21","author":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03","year":"2010"},{"issue":"5","key":"2025041015222431000_bib22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/cancers12051223","article-title":"Treatment of smoldering multiple myeloma: ready for prime time?","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2025041015222431000_bib23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025041015222431000_bib24","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025041015222431000_bib25","author":"Hill","year":"9-12  2023"},{"issue":"suppl\u00a01","key":"2025041015222431000_bib26","article-title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"},{"key":"2025041015222431000_bib27","doi-asserted-by":"crossref","first-page":"102272","DOI":"10.1016\/j.eclinm.2023.102272","article-title":"Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey","volume":"65","author":"Mohyuddin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"suppl 1","key":"2025041015222431000_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025041015222431000_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"2025041015222431000_bib30","first-page":"284","article-title":"Engaging patients in decision-making and behavior change to promote prevention","volume":"240","author":"Krist","year":"2017","journal-title":"Stud Health Technol Inform"},{"key":"2025041015222431000_bib31","article-title":"Watch and wait: focusing on shared decision-making in the treatment of smoldering myeloma","author":"Holstein","year":"5  2023","journal-title":"ASCO Daily News"},{"issue":"2","key":"2025041015222431000_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.hoc.2023.12.001","article-title":"Smoldering multiple myeloma: observation versus control versus cure","volume":"38","author":"Rajkumar","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15\u00a0suppl","key":"2025041015222431000_bib33","doi-asserted-by":"crossref","first-page":"TPS8062","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8062","article-title":"Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA","volume":"36","author":"Rajkumar","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1658\/2367943\/blood_bld-2024-025897-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1658\/2367943\/blood_bld-2024-025897-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:22:37Z","timestamp":1744284157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/15\/1658\/534407\/Efficacy-and-safety-of-daratumumab-in-intermediate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025897","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}